Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion—A Phase 2, Prospective Interventional Study
Transplantation and Cellular Therapy · 2024
DOI: 10.1016/j.jtct.2024.09.024 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Transplantation and Cellular Therapy, 2024. Verfasst von Ron Ram und 23 weiteren Autor:innen. Beteiligte Einrichtung: Tel Aviv Sourasky Medical Center, Hematology Institution, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic ad…. Hauptthemen laut MEDLINE: Nivolumab, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis, Gilead Sciences.
Abstract (Originalsprache)
Patients with large B-cell lymphoma (LBCL) in stable or progressive disease (SD/PD) at lymphodepletion prior to chimeric antigen receptor T cell (CAR-T) therapy have an inferior outcome. we hypothesized that enhancing in-vivo expansion of CAR-T cells could overcome this grim prognosis leading to improved outcomes. We conducted a phase 2 prospective trial (NCT05385263) investigating the addition of nivolumab to enhance CAR-T cell expansion and response in patients with SD/PD-LBCL. Eligible patients received 1 dose of nivolumab between day +5 and +9 post CAR-T infusion. An additional dose of nivolumab was administered on day +19 only to patients whose CAR-T cell levels in peripheral blood were below 100 cells/µL at day +7. Twenty patients were enrolled and received anti-CD19 CAR-T (Axicabtagene ciloleucel, n = 12; tisagenlecleucel, n = 8). Eight were ineligible to receive nivolumab due to active CAR-T-associated toxicities. Overall, the protocol was safe. One-month PET-CT showed an 84% overall response rate (complete response, 53%). The cumulative incidence of progression-free survival at 6 and 12 months were 50% (95% CI 36%-64%) and 42% (95% CI 26%-58%), respectively. The cumulative incidence of overall survival at 6 and 12 months were 85% (95% CI 72%-98%) and 51% (95% CI 31%-71%), respectively. Nivolumab administration significantly reduced PD-1 expression on all immune cells. CAR-T cell expansion was similar between nivolumab-eligible and noneligible patients. Notably, there was a significant enrichment of CD45RO-CD27+ CD8+ cells and CD45RO-CD27+ CD8+ CAR-T cells in the nivolumab-eligible group compared to those ineligible, suggesting that specific cell enrichment could potentially contribute to an enhanced response rate. We conclude that the addition of nivolumab based on CAR-T cell expansion in patients with SD/PD-LBCL is safe and yields promising early response rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tel Aviv Sourasky Medical Center, Hematology Institution, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: ronr@tlvmc.gov.il.
- Tel Aviv Sourasky Medical Center, Hematology Institution, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Hematology Department, Wolfson Medical Center, Holon, Israel.
- Hematology Department, Shamir Medical Center, Be'er Ya'akov, Israel.
- Hematology Department, Carmel Medical Center, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
- Hematology Department, Emek Medical Center, Afula, Israel.
Förderung
- Novartis
- Gilead Sciences
Zitieren
APA
Ram, R., Amit, O., Perry, C., Herishanu, Y., Avivi, I., Sarid, N., Apel, A., Preis, M., Aviv, A., Shapira, S., Shragai, T., Joffe, E., Shargian, L., Herzog-Tsarfati, K., Eylati, N., Acria, L., Fridberg, G., Gold, R., Glait-Santar, C., …, & Beyar-Katz, O. (2024). Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion—A Phase 2, Prospective Interventional Study. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2024.09.024
Vancouver
Ram R, Amit O, Perry C, Herishanu Y, Avivi I, Sarid N, et al. Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion—A Phase 2, Prospective Interventional Study. Transplantation and Cellular Therapy. 2024. doi:10.1016/j.jtct.2024.09.024
BibTeX
@article{Ram2024,
author = {Ram, Ron and Amit, Odelia and Perry, Chava and Herishanu, Yair and Avivi, Irit and Sarid, Nadav and Apel, Arie and Preis, Meir and Aviv, Ariel and Shapira, Shirly and Shragai, Tamir and Joffe, Erel and Shargian, Liat and Herzog-Tsarfati, Kathrin and Eylati, Nili and Acria, Luisa and Fridberg, Gil and Gold, Ronit and Glait-Santar, Chen and Kay, Sigi and Gal-Rabinovich, Kinneret and Rosenberg, Dina and Setter-Marco, Noga and Beyar-Katz, Ofrat},
title = {Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion—A Phase 2, Prospective Interventional Study},
journal = {Transplantation and Cellular Therapy},
year = {2024},
doi = {10.1016/j.jtct.2024.09.024}
}
EUVIMED